Cabaletta Bio, Inc. Common Stock
CABA US12674W1099
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Binder Gwendolyn O |
19.54 USD |
10,300 Sold |
201,211 USD |
19/01/2024 | 19/01/2024 |
Binder Gwendolyn O |
20.33 USD |
700 Sold |
14,229 USD |
19/01/2024 | 19/01/2024 |
Binder Gwendolyn O |
21.76 USD |
7,868 Sold |
171,196 USD |
19/12/2023 | 19/12/2023 |
Binder Gwendolyn O |
22.22 USD |
3,132 Sold |
69,593 USD |
19/12/2023 | 19/12/2023 |
Binder Gwendolyn O |
17.39 USD |
3,542 Sold |
61,608 USD |
20/11/2023 | 20/11/2023 |
Binder Gwendolyn O |
18.02 USD |
7,458 Sold |
134,405 USD |
20/11/2023 | 20/11/2023 |